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Background: Previous studies have shown that recurrent TB develops in about 2-5% of the patients after curative 
treatment with short-course anti-TB chemotherapy. With the advent of HIV/AIDS, the rate TB recurrence is 
anticipated to rise.  
  
Objectives:  To determine whether HIV infection and TB recurrence are associated with anti-TB drug resistance 
and the rates of ZN microscopy and culture positivity among the recurrent TB cases in western Kenya.   
 
Design and methods:  A cross-sectional study was carried out between 2007 and 2009.  Sputa from 872 
tuberculosis suspects underwent mycobacteriologic evaluation using Ziehl Neelsen smear microscopy, Lowenstein-
Jensen and BACTEC MGIT 960 culturing, and Hain’s GenoType® Mycobacterium CM and GenoType® 
Mycobacterium AS molecular identification tests.  Consenting participants were screened for HIV infection using 
Uni-GoldTM test and positives were confirmed with the enzyme linked immunosorbent assay.  Results:  In total, 
361/872 (41%) of the suspects mycobacterial disease (346 TB, 4.2% non-tuberculous mycobacterial disease).  HIV 
testing was accepted by 695 (79.7%) and 39.1% of these (272/695) were found positive.  Recurrence of TB 
constituted 44.8% (155/346) of the TB cases, with 41.9% (65/155) of them co-infected with HIV.  There was no 
significant difference in TB recurrence rates with HIV status [OR = 0.57; 95% CI: 0.29-1.13; P = 0.10].   
 
Conclusions and recommendations:  This study reports a much higher (44.8%) rate of recurrent TB, compared to 
that of National TB control Programme of 5% in 2008 and a combined retreatment rate of 14% in 2009.  The HIV 
co-infection and TB recurrence were not associated with anti-TB drug resistance.  The majority of TB recurrent 
cases were ZN smear negative (67.7%) and culture negative (80%).  The high TB recurrence observed in this 
study calls for studies to determine the proportions of the disease attributable to endogenous re-activation 
(relapse) and exogenous re-infection. 
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Introduction 
Even after effective short-course chemotherapy for 
active tuberculosis (TB), some patients experience a 
recurrent TB episode.  The recurrence of active TB after 
treatment can be due to relapse (endogenous 
reactivation) or exogenous re-infection with a new strain 
of Mycobacterium tuberculosis complex. A relapse is a 
patient previously treated for TB who was declared 
cured or treatment completed, but is diagnosed with 
bacteriologically confirmed TB again [1].  However, the 
role of exogenous re-infection in recurrent TB episodes 
 
 




has been debated for decades [2-4], but the proportion of 
recurrent TB attributable to relapse or re-infection has 
not been accurately determined [5].  However, a study 
in South Africa suggested that up to 75% of the 
recurrences after curative treatment may be caused by 
exogenous re-infections [6]. 
 
Following treatment with short-course chemotherapy, 
patients are considered to have a small risk for 
developing recurrent TB as a result of a relapse or 
exogenous re-infection [5, 7].  However, studies have 
shown HIV infection to be one of the risk factors for TB 
recurrence, as this is a major opportunistic infection in 
persons infected with HIV [8], and TB recurrence 
attributable to exogenous re-infection is more common 
in people who are HIV-positive [9].   
 
Elucidating the role of TB recurrence and its underlying 
factors in Kenya is important because the country has 
the 13th highest incidence of TB in the world 10.  
Understanding the cause for recurrence helps clinicians 
evaluate the effectiveness of therapeutic regimens.  It 
also facilitates TB prevention and control programmes 
to assess strategies and interventions. The aim of our 
study was to determine whether HIV infection and TB 
recurrence are associated with anti-TB drug resistance. 
The study also sought to determine rates of ZN 
microscopy and culture positivity among the recurrent 
TB cases. 
 
Materials and Methods 
Study Design:  A cross-sectional study was conducted. 
 
Study site and population:  The study was done at 
chest and paediatric clinics at one provincial, one level 5 
hospital and eight district hospitals in western Kenya.  
These were Busia, Bungoma, Kisumu, Migori, Kisii 
(Level 5), Narok, Kericho, Uasin Gishu and Lodwar 
district hospitals, and Nakuru Provincial General 
Hospital.  Western Kenya includes the expansive former 
Rift Valley, Nyanza and Western Provinces, with a 
cumulative population of about 19.8 million people, 
constituting about 52.1% of the Kenyan population. 
 
Sampling frame and patient characteristics:  
Participants suspected of having TB were included at 
random if they sought healthcare services at the chest 
and paediatric clinic between September 2007 and 
September 2009.  They had to be resident in western 
Kenya for at least six months and consented to 
participate in the study.  Cases that had prior treatment 
were carefully screened and those already on anti-TB 
were excluded.  Participants were suspected of having 
TB if they fulfilled the National TB Progemme criteria: 
had a cough of more than two weeks and were not 
responding to antibiotic treatment [11]. 
 
Collection of demographic data:  A questionnaire was 
administered by the designated Nurse or Clinical Officer 
in-charge of the chest and paediatric clinics to collect 
demographic and medical history data of TB suspects.  
Data collected included age, gender, previous anti-TB 
treatment, and HIV status. 
 
Collection and transportation of sputum and blood 
samples:  Three sputum specimens (spot, early 
morning, spot) were collected from 872 participants 
suspected with TB under the supervision of trained and 
competent medical staff.  The patients were requested to 
cough so that expectoration would come from deep 
down the chest as possible, and spit into a sterile 50 ml 
blue cap tubes.  For children less than 5 years of age and 
those less than 10 years of age unable to expectorate 
sputum had sputum induction performed at the Nakuru 
provincial and Kisii level 5 hospitals. The samples were 
refrigerated at 4oC awaiting transportation in cool boxes 
to the Mycobacteria Reference Laboratory, Moi 
University School of Medicine (MRL, MUSOM) 
weekly for analysis.  Samples were processed within 7 
days of collection in order to minimize loss of viability 
of the mycobacteria.  Consenting 695 participants also 
underwent phlebotomy for HIV testing.  The blood was 
delivered into Vacutainer Brand STERILE interior 
EDTA (K3) tubes and stored at –20oC awaiting 
processing.  The samples were transported in cool boxes 
to MRL, MUSOM, Eldoret, and processed within two 
weeks. 
 
HIV testing:  Screening for HIV infection was done by 
screening serum using Trinity Biotech Uni-GoldTM test 
[12] and confirmed with enzyme linked immunosorbent 
assay (ELISA) [13].    
 
Microscopic examination of sputum specimens:  
Sputum smears were examined for acid-fast bacilli 
(AFB) after staining following the Ziehl-Neelsen (ZN) 
method [14]. 
 
Isolation and identification of mycobacteria:  Sputum 
specimens were processed for isolation of mycobacteria 
following standard protocols [15].  The mycobacterial 
isolates were identified as M. tuberculosis complex or 
species of non-tuberculous mycobacteria (NTM) using 
Hain’s GenoType® Mycobacterium CM and GenoType® 
 
 




Mycobacterium AS Molecular Genetic Assays, 
following manufacturer’s instructions [16].  
 
Identification of recurrent TB cases:  Those who 
indicated to have been previously treated for TB (during 
demographic data collection) and declared cured and re-
notified at least 12 months from the date of the initial 
notification were considered recurrent TB cases [17, 
18].  This is after verification with their records held at 
the hospital. 
 
Data analysis:  Data was entered in MS Excel 8.0 and 
analysed using Epi Info version 3.5.1.  Descriptive 
statistics were used to summarize data and proportions 
compared using Chi-square (²) testing.  Univariate odds 
rations (OR) with 95% confidence intervals (CI) were 
calculated to assess risk factors (gender and age-group) 
with regard to TB infection and recurrence and HIV 
infection.  Logistic regression was used to analyze 
multivariate data.  
 
Ethical issues:  The proposal for this study was 
approved by ITROMID / KEMRI’s Scientific Steering 
Committee (SSC) and Ethical Review Committee 
(ERC) [SSC No. 837] and by Moi University School of 
Medicine (MU-SOM) / Moi Teaching and Referral 
Hospital (MTRH) Institutional Research and Ethics 
Committee (IREC) [FAN No.00092].  Clearance was 
also obtained from respective district health authorities 
and hospital administrations. Informed consent / assent 
were obtained from candidates or their guardians before 
they were enrolled into the study.  The purpose of the 
study was explained to the potential candidates in 
English, Kiswahili or a local language before consent 
was sought. Code numbers rather than names were used 
to identify candidates in order to maintain 
confidentiality.  The study did not expose candidates to 
any unusual risks as competent hospital staff obtained 




A total of 872 suspected TB cases were enrolled into the 
study, 54.9% (477) males and 45.1% (393) females. 
Their median age was 32 years.  The majority of study 
participants (33.1%) were in the 25-34 age bracket, 
followed by those in the 35-44 (21.8%) and 15-24 
(18.7%) age categories respectively. Children in the 0-
14 age-group constituted 4.6%, of the TB suspects, with 
the under fives (<5 years) contributing 0.6%. 
 
Microscopy and culture:  A total 361 participants were 
diagnosed with mycobacterial disease, 346 (95.8%) 
being TB, and 15 (4.2%) being NTM disease cases.  
Hence, 39.7% (346/872) of the participants had TB, 
62.1% (215/346) males and 37.9% females. Children 
below 15 years constituted 4.9% (17/346) of the TB 
cases. 
 
Recurrences and HIV infection:  A total of 155 
(44.8%) of the TB cases were recurrences, having 
previously been treated for TB and declared cured.  
Questionnaire data and hospital records regarding 
history of TB treatment of participants were fully in 
agreement.  No treatment failures or default cases were 
observed in this study.  Males constituted 54.2 % 
(84/155) and females 45.8% (71/155) of the recurrent 
TB cases.  A total of 50 (32.3%) of the TB recurrent 
cases were ZN smear positive of which 25 were culture 
positive, and 105 (67.7%) cases were smear negative of 
which 6 were culture positive. Similarly, a total of 31 
(20%) recurrent cases were culture positive and 124 
(80%) culture negative. A total of 65 (41.9%) of these 
cases were HIV sero-positive, 70 (45.2%) cases HIV 
sero-negative, and the HIV status of 20 (12.9%) cases 
was unknown. 
 
The majority (35.2%) of the recurrences were in the 25-
34 age-group, followed by the 35-44 age-group with 
23.9%.  Also within age-groups, recurrences were more 
frequent among males in the 25-54 age-group.  There 
was no statistically significant difference in TB 
recurrence between the genders [OR = 1.04; 95% CI: 
0.73-1.47; P = 0.84] and HIV status [OR = 0.57; 95% 

































An episode of recurrent TB has been defined as a case 
re-notified at least 12 months from the date of the initial 
notification [18]. This is based on the reporting criteria 
of Enhanced Tuberculosis Surveillance that a year has to 
elapse before a case in the same patient can be notified 
again, and that any case reported from the same patient 
twice within a year is considered a single episode. The 
assumption is that most cases would be expected to have 
completed their treatment within 12 months, which is 
also why 12 months is the standard cut-off time at 
which treatment outcomes are recorded [18, 19]. 
Previous studies have shown that recurrent TB develops 
in about 2-5% of the patients after curative treatment 
with short-course anti-TB chemotherapy [20]. Among 
TB patients cured by short-course treatment in trial 
conditions, up to 7% develop recurrent TB needing 
retreatment within 1 to 2 years [7].  Also re-infections 
with new strains of M. tuberculosis complex may play a 
significant role in the recurrence of TB especially in 
settings with a high prevalence of the disease [21]. 
 
The high TB recurrence rate of 44.8% reported in this 
study compared to national rates by the 2007 and 2008 
reported by the Division of Leprosy, TB and Lung 
Disease (DLTLD) [22, 23] is highly discouraging and 
deserves major attention.  In the official 2007 DLTLD 
[22] annual report, retreatment cases contributed 9% of 
the TB cases, of which 3% were classified as PTB 
relapse category.  The rest were recurrent smear 
negative PTB and EPTB (4%), treatment failures 
(0.1%), and return after default (1.4%).  The 2008 





















smear positive relapse rate of 3% and a combined 
recurrent smear negative pulmonary TB and extra-
pulmonary TB rate of 5%.  However, in the 2009 annual 
report, the DLTLD [24] reports a combined retreatment 
rate of 14%.  In all these reports however, the DLTLD 
cautions that due to the high prevalence of HIV in this 
population it is possible that some of the cases reported 
as TB could represent undiagnosed HIV related disease. 
Many National TB Control Programmes in Sub-Saharan 
Africa countries have no capacity to distinguish between 
relapse (endogenous reactivation) from (exogenous) 
reinfection TB, which constitute recurrent TB. It is not 
clear how the DLTLD identified TB relapse cases given 
in their annual reports.  This is because diagnosis and 
treatment of new TB cases at majority of health 
facilities in Kenya is based on clinical symptoms, ZN 
smear microscopy, and occasionally augmented with 
chest X-ray in some of the health facilities. 
 
In the current study males dominated females with 
54.2% of the recurrent TB cases, just like in TB and TB-
HIV co-infection.  The majority (36.8%) of the 
recurrences were in the 25-34 year age-group, one of the 
most productive segments of society.  Even if there was 
no significant difference in recurrence rate between 
genders and HIV status, the relatively high (44.8%) 
recurrence rate observed in the current study require 
further investigation to distinguish re-activations from 
re-infection as the predominant cause.  This may lead to 
consideration of further intensification of the initial 
regimen or use of secondary prophylaxis [7].  Results of 
Age-group N (%) Males (%) Females (%) OR 95%CI P-value 
0-14 5(3.2) 1(0.6) 4(2.6) 5.714 0.576-56.675 0.137 
15-24 18(11.6) 9(5.8) 9(6.8) 0.960 0.360-2.555 0.934 
25-34 57(36.8) 32(20.6) 25(16.1) 1.006 0.561-1.804 0.985 
35-44 40(25.8) 23(14.8) 17(11.0) 0.967 0.478-1.957 0.925 
45-54 17(11.0) 10(6.5 7(4.5) 1.038 0.354-3.040 0.946 
55-64 12(7.7) 4(2.6) 8(5.2) 2.941 0.763-11.336 0.117 
> 64 6(3.9) 5(3.2) 1(0.6) 0.182 0.020-1.690 0.134 
Total 155(100) 84(54.2) 71(45.8) 1.037 0.734-1.469 0.839 
 
 




the current study are also indicative of the necessity for 
evaluation of the performance of the short course (SCC) 
TB chemotherapy in Kenya.  Kenya has been fully 
under directly observed therapy short course (DOTS) 
programme since 1998 [24].  However, it cannot be 
concluded categorically that DOTS functions as may be 
expected on basis of its naming.  In the current study for 
instance, patients in western Kenya were provided with 
drugs to take at home for at least two weeks and 
adherence is not routinely checked.  Therefore, it is 
unknown what the degree of compliance is.  The degree 
of compliance can only be determined if differentiation 
between relapse and re-infection is established.  From 
results of the current study, it becomes clear that this 
major issue should be addressed appropriately in order 
to pin point the underlying reasons for such a high rate 
of recurrence.  However, acquired resistance does not 
seem to play a major role in this problem, since the 27 
M. tuberculosis complex isolates obtained from the 
recurrent TB cases and subjected to first-line anti-TB 
drug susceptibility testing were all susceptible to 
streptomycin (STR), ethambutol (EMB) and rifampicin 
(RIF).  Only 3 isolates from cases co-infected with HIV 
were resistant to isoniazid (INH). 
 
However, the present study could not determine whether 
the recurrences were due to endogenous re-activations 
or exogenous re-infection, or even multiple/super 
infections since there were no M. tuberculosis complex 
isolates from previous disease episodes of the study 
candidates available.  However, DNA fingerprinting 
studies in South Africa have reported a higher rate of 
reactivation (74.8%) versus recent transmission or re-
infection (25.2%) [6]. The DNA fingerprinting of M. 
tuberculosis complex is an excellent tool to address this 
important issue and it is clear this type of molecular 
epidemiology becomes highly important in determining 
whether a recurrent TB episode is due to endogenous 
reactivation, meaning treatment failure, or exogenous 
re-infection with a different strain [25, 2].  Different M. 
tuberculosis complex strains can be differentiated using 
information on genetic markers and their distribution in 
the genome.  Among persons with recurrent TB, if the 
isolates from two TB episodes have the same genotype, 
the second episode is a relapse, defined as an 
endogenous reactivation; otherwise, it is defined as 
exogenous re-infection [26]. 
 
Other studies have reported proportions of re-infection 
among recurrent TB cases ranging from 1.2-7% in low-
incidence areas [27], 12-75% in medium-incidence 
areas [28], and 23-75% in high-incidence areas which 
include India, China, Indonesia, Nigeria, South Africa 
and former Soviet states [29].  However, re-infection is 
an uncommon cause of recurrent TB in low TB 
prevalence settings [28, 30].  For instance, Jasmer et al. 
[28] evaluated cases of recurrent TB in two prospective 
clinical trials in Canada and United States by 
genotyping using IS6110.  They reported 96% of the 
recurrences to have been caused by the same genotype; 
only 4% had a different genotype and were categorized 
as re-infection, indicating that recurrent TB in the USA 
and Canada, countries with low rates of TB, is rarely 
due to re-infection with a new strain of M. tuberculosis 
[28]. 
 
The significantly high rate of TB (39.7%) observed in 
the current study compared to the national standards to 
20-25% reported by the DLTLD is worthy noting. The 
difference could be attributed to regional variations of 
TB disease rate since the national reports cover the 
whole country with some regions have low disease rate.  
It may also be attributed to challenges faced by the 
DLTLD in data collection countrywide which may lead 
to inaccurate data collection.  The present study also 
observed a high TB-HIV co-infection prevalence of 
41.8% even though this was slightly lower than those 
reported by the DLTLD.  The 2007, 2008 and 2009 
DLTLD annual reports give TB-HIV co-infection 
prevalence of 48%, 45% and 44%, respectively.  The 
discrepancy could be attributed to some TB cases 
declining to undergo HIV testing, or decreasing HIV 
infection rate.  However, the TB-HIV co-infection rate 
in the present study was higher than the global 
prevalence of 14.8% during the same period [10]. 
 
Conclusions and Recommendations 
The HIV co-infection and TB recurrence were not 
associated with anti-TB drug resistance.  The majority 
of TB recurrent cases were ZN smear negative (67.7%) 
and culture negative (80%).  The high TB recurrence 
rate reported in the current study requires further 
investigation to distinguish relapse (endogenous 
reactivation) from exogenous re-infection as the 
predominant cause.  In order to know whether the M. 
tuberculosis population structure is changing toward 
genotypes with selective advantage to circumvent BCG 
induced immunity and to become resistant against 
tuberculostatics / tuberculocidals, it would be wise to 
compare the genotypes found in young people (recent 
infections) and older people (more frequently due to 
endogenous re-infections of remote infections).  What is 
found in old people is a reflection of the past 
(reactivation), while what is found in young people tells 
what strains are currently circulating and will be found 
in the future. 
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